1. J Med Chem. 2005 Sep 22;48(19):5888-91. doi: 10.1021/jm050598r.

Discovery and characterization of aminopiperidinecoumarin melanin concentrating 
hormone receptor 1 antagonists.

Kym PR(1), Iyengar R, Souers AJ, Lynch JK, Judd AS, Gao J, Freeman J, Mulhern M, 
Zhao G, Vasudevan A, Wodka D, Blackburn C, Brown J, Che JL, Cullis C, Lai SJ, 
LaMarche MJ, Marsilje T, Roses J, Sells T, Geddes B, Govek E, Patane M, Fry D, 
Dayton BD, Brodjian S, Falls D, Brune M, Bush E, Shapiro R, Knourek-Segel V, Fey 
T, McDowell C, Reinhart GA, Preusser LC, Marsh K, Hernandez L, Sham HL, Collins 
CA.

Author information:
(1)Metabolic Disease Research, Abbott Laboratories, 100 Abbott Park Road, Abbott 
Park, Illinois 60064, USA. phil.r.kym@abbott.com

4-(1-Benzo[1,3]dioxol-5-ylmethylpiperidine-4-ylmethyl)-6-chlorochromen-2-one (7) 
is a potent, orally bioavailable melanin concentrating hormone receptor 1 
(MCHr1) antagonist that causes dose-dependent weight loss in diet-induced obese 
mice. Further evaluation of 7 in an anesthetized dog model of cardiovascular 
safety revealed adverse hemodynamic effects at a plasma concentration comparable 
to the minimally effective therapeutic concentration. These results highlight 
the need for scrutiny of the cardiovascular safety profile of MCHr1 antagonists.

DOI: 10.1021/jm050598r
PMID: 16161992 [Indexed for MEDLINE]
